Disease · MONDO_0015274

chronic beryllium disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic beryllium disease. Diseases, record MONDO_0015274. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015274

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic beryllium disease; Open Targets
Open Targets ID: MONDO_0015274; Open Targets
Other names: Berylliosis (disorder), berylliosis, beryllium poisoning, chronic berylliosis, chronic beryllium lung disease; Open Targets
Disease Ontology: DOID:10322; Disease Ontology
MeSH: D001607; MeSH
Orphanet: ORPHA:133; Orphanet
Highest stage of its drugs: Approval, for 1 of its 3 drugs, from DailyMed; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
MESALAMINE	CHEMBL704	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	1	Arachidonate 5-lipoxygenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/240	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	1	Peroxisome proliferator-activated receptor gamma agonist	Phase 1/2	https://conductscience.org/library/genes/5468	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/5743	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 1/2	https://conductscience.org/library/genes/7124	Drugs and targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01088243	Targeting Oxidative Stress in Chronic Beryllium Disease	Phase 1/2	18	2017-12-12	Chronic Beryllium Disease	MESALAMINE	Its record names the disease	ClinicalTrials.gov
NCT00111917	Beryllium Infliximab Study: Clinical Interventional Trial	Phase 1/2	13	2014-09-25	Berylliosis, Beryllium Disease	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Mesalamine vs Placebo: serious adverse events	0 of 13	0 of 5	18	NCT01088243	Trial comparisons
Group 1 - Infliximab vs Group 2 - Placebo: serious adverse events	3 of 8	1 of 3	11	NCT00111917	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
22974830	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015274

GET https://conductscience.org/api/diseases/v1/MONDO_0015274/drugs

API reference For AI assistants